Induction of chondro-, osteo- and adipogenesis in embryonic stem cells by bone morphogenetic protein-2: Effect of cofactors on differentiating lineages
© zur Nieden et al; licensee BioMed Central Ltd. 2005
Received: 03 September 2004
Accepted: 26 January 2005
Published: 26 January 2005
Recently, tissue engineering has merged with stem cell technology with interest to develop new sources of transplantable material for injury or disease treatment. Eminently interesting, are bone and joint injuries/disorders because of the low self-regenerating capacity of the matrix secreting cells, particularly chondrocytes. ES cells have the unlimited capacity to self-renew and maintain their pluripotency in culture. Upon induction of various signals they will then differentiate into distinctive cell types such as neurons, cardiomyocytes and osteoblasts.
We present here that BMP-2 can drive ES cells to the cartilage, osteoblast or adipogenic fate depending on supplementary co-factors. TGFβ1, insulin and ascorbic acid were identified as signals that together with BMP-2 induce a chondrocytic phenotype that is characterized by increased expression of cartilage marker genes in a timely co-ordinated fashion. Expression of collagen type IIB and aggrecan, indicative of a fully mature state, continuously ascend until reaching a peak at day 32 of culture to approximately 80-fold over control values. Sox9 and scleraxis, cartilage specific transcription factors, are highly expressed at very early stages and show decreased expression over the time course of EB differentiation. Some smaller proteoglycans, such as decorin and biglycan, are expressed at earlier stages. Overall, proteoglycan biosynthesis is up-regulated 7-fold in response to the supplements added. BMP-2 induced chondrocytes undergo hypertrophy and begin to alter their expression profile towards osteoblasts. Supplying mineralization factors such as β-glycerophosphate and vitamin D3 with the culture medium can facilitate this process. Moreover, gene expression studies show that adipocytes can also differentiate from BMP-2 treated ES cells.
Ultimately, we have found that ES cells can be successfully triggered to differentiate into chondrocyte-like cells, which can further alter their fate to become hypertrophic, and adipocytes. Compared with previous reports using a brief BMP-2 supplementation early in differentiation, prolonged exposure increased chondrogenic output, while supplementation with insulin and ascorbic acid prevented dedifferentiation. These results provide a foundation for the use of ES cells as a potential therapy in joint injury and disease.
Articular cartilage is composed of extracellular matrix (ECM), the matrix-secreting chondrocyte and water, which all account for the tissue's characteristic rigidity as well as its flexibility. These features are necessary in order to warrant life-long survival of the cartilage tissue, especially in the joint where it has to endure pressure forces caused by movement. Chondrocytes arise from a mesenchymal progenitor during development, the same progenitor that gives rise to other mesenchymal cell types including osteoblasts, adipocytes and myocytes. Bone formation can either be endochondral, when chondrocytes mature and calcify to provide a matrix for the invading osteoprogenitors, or intramembraneous involving ossification directly from a mesenchymal ancestor. All these diverse cell types may arise from the same precursor, but are distinguished by specific morphological features and with that, a certain set of characteristic proteins including transcription factors that control their differentiation.
Two chondrocyte-specific transcription factors have been identified, Sox9, a member of the SOX-family of transcription factors, and Scleraxis, a member of the basic helix-loop-helix transcription factors [1, 2]. However, most of the exclusive markers for cartilage tissue reside in the ECM. The predominant form of collagen in mature cartilage is collagen type IIB, whereas the alternatively spliced collagen IIA is found primarily during development . Aggrecan is the major proteoglycan species in cartilage . The transition of chondrocytes into hypertrophy is distinguished by a change in expression of Cbfa1, the osteoblast-specific transcription factor, which is also switched on during intramembraneous ossification. Distinctive to cartilage, the major collagen molecule in osseus matrix is collagen type I. In contrast, the transcription factors controlling adipogenesis are C/EBPα and PPARγ, which transactivate subsets of genes as a function of either trans-acting factor alone or requiring the co-operative effort of both . C/EBPα is known to bind to and transactivate particularly the promotors of the SCD1, aP2 and the Glut4 genes [6, 7], all highly characteristic of the adipocyte phenotype.
For decades, the treatment of degenerative cartilage and bone diseases has been a challenge for orthopaedic surgeons due to the apparent inability of cartilage and bone to repair itself. Arthritis, a degenerative joint condition, is one of the most prevalent chronic health conditions in North America. Arthritis can devastate people, but to date there is no effective therapy available and patients can only be helped by surgical joint replacement. An inherent major concern is the limited availability of autografts, which significantly reduces the choice of treatable defects. However, new approaches to cell grafting are being developed in this field: increased yields of cells are achieved by the usage of bioreactors and growth factor administration, such as TGFβ1 and BMPs [8, 9]. Additionally, stem cells are being discovered as a new source of transplantable material.
Embryonic stem cells represent a valuable source for cell transplantation since their characteristic features include an unlimited self-renewing capacity and a multilineage differentiation potential [10, 11]. In fact, ES-derived glial precursors and cardiomyocytes have been successfully transplanted, integrated and shown to be functionally active in the transplantation site [12, 13]. The yield of differentiation of ES cells into an intended lineage can be greatly enhanced by the addition of growth factors or induction substances. Whereas protocols for the differentiation of cardiomyocytes, neuronal cell types, insulin-producing cells or adipocytes from ES cells have been available for many years [14–17], only recently their differentiation into elements of the skeleton has been reported [18–20]. Our group has previously shown that vitamin D3 forces ES cells to undergo osteogenesis . Kramer et al. have reported in 2000 that BMP-2 pushes ES cells to the chondrogenic fate when added during days 3–5 of EB differentiation . Those ES-derived chondrocytes possess a certain plasticity to undergo hypertrophy and calcify .
We show here, that prolonged treatment of differentiating ES cell cultures with BMP-2 in synergy with TGFβ1, insulin and ascorbic acid leads to improved chondrogenesis in vitro. Compared to the brief supplementation described by Kramer et al. , the expression of chondrocyte-specific marker genes was highly up-regulated while proteoglycan content revealed an increased chondrocytic yield from 7.26% to 57.03%. As described by other groups , ES-derived chondrocytes become hypertrophic and calcify. However, spontaneous calcification did not reach mineralization levels that are found in vitamin D3 induced ES-derived osteoblasts . Yet, supplementation of chondrocyte-cultures with β-glycerophosphate, ascorbic acid and vitamin D3 starting at day 20 rescued the osteoblast phenotype. In many differentiations, we also observed an accumulation of lipid droplets and an up-regulation of adipocyte-specific genes. This direction towards adipocyte differentiation varied with the use of specific co-factors, suggesting that in the future, such spurious differentiation may be controlled, once the pathways involved in adipogenesis are better understood.
Characterization of chondrocyte-like cells derived from ES cells
Dependence of gene expression patterns and proteoglycan synthesis on BMP-2
Quantitative RT-PCR was used to examine the variability of RNA expression of various cartilage-specific genes in response to BMP-2. Previously, chondrogenesis was induced in ES cells using 2 ng/ml BMP-2 on days three to five of EB formation, when early mesodermal markers such as Brachyury and BMP-4 are expressed [21, 23, 24]. To improve chondrogenesis, we investigated whether a higher concentration of BMP-2 (10 ng/ml) could increase chondrocyte-specific gene expression. Total RNA was extracted on day 32 and quantitative real-time PCR was carried out. Expression of genes of interest in cultures supplemented with 10 ng/ml BMP-2 was normalized to GAPDH expression and compared to cultures supplemented with 2 ng/ml (fig. 1E), which were set as 1. Expression of the small leucine-rich proteoglycans biglycan and decorin was increased 1.6 fold upon supplementation with 10 ng/ml BMP-2 (P < 0.01). Neither link protein expression nor Sox9 or scleraxis expression were affected by the higher dosage. However, expression of aggrecan and the collagen type II isoforms A and B, which are specific for mature chondrocytes, were significantly increased compared to the low BMP-2 concentration described by Kramer et al. (P < 0.001). The degree of chondrogenic differentiation under influence of BMP-2 was further quantified by metachromatic detection of proteoglycans (fig. 1F). Secreted proteoglycans were extracted on day 32 of culture with guanidine/HCl and combined with dimethylmethylenblue. Based on our measurement of aggrecan, the synthesis of proteoglycan proteins is also increased under the influence of BMP-2. BMP-2 at 2 ng/ml initiated an induction in proteoglycan synthesis of about 2 fold (P < 0.01), whereas 10 ng/ml BMP-2 increased the proteoglycan content of EBs 2.3 fold (P < 0.1) compared to non-treated controls. This data shows, that BMP-2 causes the induced synthesis of negatively charged extracellular matrix, characterized by proteoglycans.
Additive effect of TGFβ1, insulin and ascorbic acid on BMP-2 induced chondrogenesis
Combinations of medium supplements used at different culture stages
Day 3–5 (hanging drops)
Day 5 onwards (attached culture)
Surprisingly, when BMP-2 supplementation was maintained throughout the culture period (combination G), a dramatic increase of marker gene expression was seen. Aggrecan and COL IIB were up-regulated over 80-fold above controls and link protein and COL IIA expression was increased to 35- and 16-fold, respectively. Here, scleraxis and Sox9 expression behaved conversely. Supplement combination G showed significant decreases of scleraxis and Sox9 expression to 50 and 87% of the control, respectively (P = 0.001). Deferral of the expression of these transcription factors in favour of chondrogenic differentiation characterizes BMP-2 induced differentiation, whereupon chondrogenic processes are furthermore enhanced by TGFβ1, insulin and ascorbic acid.
The determination of proteoglycan content was used to confirm the results obtained by quantitative RT-PCR for all supplement combinations (fig. 2B). TGFβ1 alone (combination B) did not alter proteoglycan levels compared to controls, and in combination with BMP-2 decreased the proteoglycan content of EBs compared to BMP-2 alone (combination C). Insulin and ascorbic acid did not enhance the proteoglycan synthesis in combination with TGFβ1, but caused a 4.2-fold increase in combination with BMP-2 (combination E, P = 0.01). In agreement with aggrecan gene expression, combinations F and G generated a massive 7-fold induction of proteoglycans in EBs (P = 0.001).
Kinetic analysis of cartilage-specific gene expression during EB differentiation
ES-derived chondrocytes undergo hypertrophy and mineralize
Induction of adipocyte differentiation
In this study, we demonstrate an improved method for driving ES cells to a cartilaginous fate when stimulated with BMP-2 and TGFβ1. In the early phase of differentiation, BMP-2 operates by directing differentiation towards the cartilage lineage and acting on chondroprogenitors. During later differentiation adding mineralizing agents can trigger hypertrophy and mineralization of the ES-derived chondrocytes. In the embryo, maturation of chondrocytes in the process of endochondral ossification follows a timely regulated developmental program, whereby cellular stages can be delimitated molecularly. During ES cell differentiation into chondrocytes, developmental processes follow the same pattern, as judged by the gene expression patterns observed. Chondrocytes, osteoblasts and adipocytes are thought to arise from the same mesenchymal progenitor. Based on our previous observations around VD3-induced osteogenesis, we have already hypothesized that during the first 5 days of differentiation mesodermal progenitors develop, which then are susceptible to the VD3 treatment . Treatment of the cultures with TGFβ1 at days 3–5 may augment the number of mesenchymal progenitors, as TGFβ1 is thought to inhibit the proliferation of most cells, but to stimulate some mesenchymal cells such as osteoblasts and chondrocytes . It was not surprising to see adipocytes develop in many of our cultures, as they represent another member of the TGFβ1 promoted mesodermal lineage.
The gain of adipose characteristics in culture is hallmarked by: a) the appearance of cytoplasmic lipid droplets, b) the acquisition of insulin sensitivity with regard to glucose uptake (GLUT4) and c) the expression and secretion of numerous bioactive molecules . All of these characteristics of in vivo adipogenesis were met in the EBs treated with BMP-2, TGFβ1, insulin and ascorbic acid. Indeed, a future challenge for improving adipogenic cultures will be the discovery of regulatory pathways in adipogenesis. Once identified, such pathways may be antagonized in order to enhance ES differentiation into chondrocytes.
During the revision of this paper, a study was published describing that the overexpression of the sox triad, namely Sox9, Sox5 and Sox6, markedly increased chondrocyte marker gene expression (collagen type 2, aggrecan) in ES cells within 3 days . Here, TGFβ1, BMP-2, IGF-1 and FGF-2 had no affect on the immediate regulation of these genes. In our differentiation system, Sox9 is elevated very early during differentiation at day 5 (data not shown) underlining its role as an early controller of chondrogenesis. We have shown here that BMP-2 regulates later processes in cartilage development. Marker gene expression levels reached upon overexpression of the Sox trio do not meet the levels we have observed in this study, suggesting that Sox9 may be necessary but not sufficient do direct all progenitors to the chondrocytic lineage.
Earlier this year, another study portrayed chondrogenesis in ES cells using encapsulation in alginate . The usage of a 3D culture system led to an increase in Col II and aggrecan expression of about 1.5- to 2-fold above the regular 2D system of plating EBs. Comparing those values to the 80- to 90-fold up-regulation described here, it is clear that three-dimensional signals also need to be incorporated into chondrocyte differentiations to increase differentiation efficiency.
Articular cartilage has been refractory to repair following degeneration. Despite its limited capacity to self-repair, cartilage is replete with cells capable of undergoing mitotic division . Current hypotheses suggest that cells may be constrained by their ECM, thus preventing expansion and differentiation or that there is a limit in the bioactive molecules, which support chondrogenesis [31, 32]. Engineering bone or cartilage usually requires the handling of autologous cells. Cells are released from the ECM using collagenase and hyaluronidase. However, the small number of available progenitors, within the tissue can be problematic . Moreover, the ability of these harvested cells to proliferate is limited in the elderly, where most degenerative joint disorders occur. The outcome of conventional surgical treatment including joint resurfacing or biological autografts has been unsatisfactory following long-term evaluation . This failure is caused by insufficient repair resulting in the formation of mechanically inadequate resident fibrocartilage. These disappointing results and the limited therapeutic opportunities have led investigators to focus on more appropriate bioregenerative tissue engineering approaches, which could be specifically tailored for a patient's needs.
Pluripotent ES cells are now being contemplated as a new cell source for tissue engineering since they are the most multifaceted cells amongst all stem cells. While their pluripotency offers a huge potential for cell therapies directed against a wide spectrum of degenerative diseases that are ineffectively treated by traditional approaches, it also poses challenge for controlling developmental fate in the recipient. Understanding the developmental pathways regulating ES cell differentiation, will enable the creation of a cell source that can be manipulated to correct for a particular defect.
This study was designed to improve upon the number of differentiated cells needed for the in vitro development of functional cartilage as this represents a first critical step in applying ES cells clinically. Additionally, the presented in vitro model of chondrogenesis may be useful for in vitro embryotoxicity tests  as also serve as a new tool in identifying molecular pathways that underlie chondrogenesis. Compared to other in vitro models of chondrogenesis, this model incorporates all steps of development beginning with a pluripotent, uncommitted cell and thus might further our understanding of normally unamendable stages of development.
This study was particularly designed to improve chondrocyte yields from ES cells by investigating the effect of higher BMP-2 concentrations and the complementary effects of TGFβ1, insulin and ascorbic acid. By examining gene expression responses and cell sorting for GFP-expressing chondrocytes, we demonstrate that using a higher concentration of BMP-2 in combination with appropriate co-factors, we can significantly enhance ES cell derived chondrogenesis compared to known protocols. In addition, we document that ES-derived chondrocytes behave naturally as they undergo hypertrophy.
We show that EBs supplemented with BMP-2 also result in a small amount of adipogenesis in vitro. This observation is consistent with knowledge that adipocytes, chondrocytes and osteoblasts arise from the same mesenchymal ancestor. Accordingly, in the future, it will be necessary to understand how to discriminate these populations for cytotherapeutic applications. At this time, the presented in vitro model allows the study of mechanisms involved in BMP-2 induced chondrogenesis, osteogenesis and adipogenesis.
Cell culture and differentiation of embryonic stem cells
Cells of the mouse ES cell line D3 (American Type Culture Collection, Rockville, Maryland, USA) were kept in permanent culture as described [35, 18] with the additive Leukemia Inhibitory Factor (1000 U/ml, Gibco Life Technologies, Karlsruhe, Germany). Differentiation was initiated in hanging drops. Cells condensed to form EBs, which were transferred on day 3 into suspension culture. At day 5, EBs were plated into 24-well tissue culture primaria plates (Falcon, Heidelberg, Germany). The effects of BMP-2 [2 or 10 ng/ml], TGFβ1 [2 ng/ml], insulin [1 μg/ml] and ascorbic acid [50 μg/ml] in various combinations on the differentiation of chondrocytes were examined. Medium was changed every second day.
Alcian blue staining
Proteoglycans secreted by ES-cell derived chondrocytes were stained with Alcian blue. Cultures were fixed in 2.5% glutaraldehyde, 25 mM sodium acetate, 0.4 M MgCl2 containing 0.05% Alcian blue for 48 h. Wash steps in 3% acetic acid, 3% acetic acid/25% ethanol and 3% acetic acid/50% ethanol reduced unspecific binding of the dye.
Metachromatic test with 1.9-dimethylmethylenblue
Proteoglycan content of differentiated cultures was determined with the DMMB-assay . Proteoglycans were extracted in 4 M guanidin-HCl/0.05 M sodium acetate (pH 5.8) containing 100 mM 6-amino-caproic acid, 10 mM EDTA, 5 mM benzamidine/HCl, 10 mM N-ethylmaleimide, 0.4 mM pepstatin, 1 mM PMSF and 1 μg/ml soy bean trypsin inhibitor for 48 h at 4°C. Non-completely digested cells were separated from the lysate by centrifugation. Lysate was mixed with DMMB reagent (0.16% w/v DMMB in 0.2% formic acid containing 2 mg/ml sodium formate, pH 3.5) and changes in absorption were detected at 535 nm in a spectrophotometer. Concentration of proteoglycans in samples was read against a standard curve of chondroitin sulfate C.
Embryoid bodies were differentiated to the chondrocyte lineage with BMP-2, TGFβ1, insulin and ascorbic acid and fixed on day 32 with ice-cold methanol:aceton (7:3) at -20°C for 10 min. For staining with anti-collagen type II (Chemicon, MAB 8887) cultures were digested with pepsin for 15 min at 37°C. Staining with anti-adult proteoglycan (Chemicon MAB 2015) was performed after a 1 h digest with chondroitinase ABC at room temperature. Cells were overlaid with the appropriate dilution of the first antibodies in PBS, 10% FCS at 4°C over night. The corresponding secondary antibody, an AlexaFluor 488 goat anti-mouse IgG (H+L), F(ab')2 fragment (A-11006, Molecular Probes, Leiden, The Netherlands) was incubated with the cells for 2 h at room temperature. Cultures were observed in a Leica Fluovert FU fluorescent microscope (Leitz, Wetzlar) with an excitation wavelength of 495 and an emission wavelength of 519 nm.
RNA isolation, RT-PCR and real-time quantitative RT-PCR
Sequences and annealing temperatures for the primer sets used in RT-PCR
Tm in °C
Collagen type II
Collagen type X
Quantification of chondrocyte yield by FACS
The GFP expressing plasmid pEGFP-1 (Clontech) under the control of the Aggrecan promotor (kind gift of John R. Matyas) was stably transfected into D3 ES cells using Invitrogen's Effectene system followed by neomycin selection. Genomic integration of the reporter was analyzed by RT-PCR with specific GFP primers (data not shown). ES cells were differentiated along the chondrocyte lineage, trypsinized into a single cell suspension and subjected to fluorescence-activated cell sorting on day 32 using a FACS Calibur instrument and the CellQuest software from Becton Dickinson (Germany). Ten thousand events were registered per sample and analysis of whole cells was performed using appropriate scatter gates to avoid cellular debris and aggregates.
Cells were washed with PBS and without any fixation directly overlaid with Oil-red-O working solution (0.18% Oil-Red-O dye/60% propanol) After a staining period of 15 minutes, ES cell cultures were rinsed in distilled water until desired colour was achieved.
Data analysis was performed with ONE-WAY ANOVA on n = 3 experiments using SigmaStat version 2.03 (SPSS Inc., San Rafael, CA, USA).
List of abbreviations
Adipocyte determination- and differentiation-dependent factor 1
Fatty acid-binding protein
Bone Morphogenetic Protein
Core binding factor alpha 1
Fetal calf serum
Fibroblast growth factor
Glucose transporter 4
Insulin-like growth factor
Peroxisome proliferator-activated receptor
Steroyl CoA desaturase
Sry-related high mobility group box
Transforming Growth Factor beta
This study was funded in part by the German Ministry of Education, Science, Research and Technology (BMBF) grant no. 0312314. NZN is supported by a post-doctoral fellowship from the Alberta Heritage Foundation of Medical Research (AHFMR). DER is an AHFMR Senior Scholar. The authors are thankful to the FACS core facility of the Faculty of Medicine for performing flow cytometry and to Dr. John R. Matyas for providing the Aggrecan-GFP construct. We furthermore appreciate the technical assistance of Lesley Davis.
- Bi W, Deng JM, Zhang Z, Behringer RR, deCrombrugghe B: Sox9 is required for cartilage formation. Nat Genet. 1999, 22: 85-89. 10.1038/8792.View ArticlePubMedGoogle Scholar
- Cserjesi P, Brown D, Ligon KL, Lyons GE, Copeland NG, Gilbert DJ, Jenkins NA, Olson EN: Scleraxis: a basic helix-loop-helix protein that prefigures skeletal formation during mouse embryogenesis. Development. 1995, 121: 1099-1110.PubMedGoogle Scholar
- Ryan MC, Sandell LJ: Differential expression of a cysteine-rich domain in the NH2-terminal propeptide of type II (cartilage) procollagen. J Biol Chem. 1990, 265: 10334-10339.PubMedGoogle Scholar
- Heinegard D, Paulsson M: Extracellular matrix biochemistry. Edited by: Piez KA, Reddi AH. 1984, Elsevier, New York, 277-Google Scholar
- Gregoire FM, Smas CM, Sul HS: Understanding adipocyte differentiation. Physiol Rev. 1998, 78 (3): 783-809.PubMedGoogle Scholar
- Christy RJ, Yang VW, Ntambi JM, Geiman DE, Landschulz WH, Friedman AD, Nakabeppu Y, Kelly TJ, Lane MD: Differentiation-induced gene expression in 3T3-L1 preadipocytes: CCAAT/enhancer binding protein interacts with and activates the promoters of two adipocyte-specific genes. Genes Dev. 1989, 3 (9): 1323-1335.View ArticlePubMedGoogle Scholar
- Kaestner KH, Christy RJ, Lane MD: Mouse insulin-responsive glucose transporter gene: characterization of the gene and trans-activation by the CCAAT/enhancer binding protein. Proc Natl Acad Sci U S A. 1990, 87 (1): 251-255.PubMed CentralView ArticlePubMedGoogle Scholar
- Roberts AB, Sporn MB: The transforming growth factor-betas. Peptide growth factors and their receptors. Edited by: Sporn MB, Roberts AB. 1990, Springer Verlag, Heidelberg, Germany, 421-472.Google Scholar
- Chen P, Carrington JL, Hammonds RG, Reddi AH: Stimulation of chondrogenesis in limb bud mesoderm cells by recombinant human bone morphogenetic protein 2B (BMP-2B) and modulation by transforming growth factor β1 and β2. Exp Cell Res. 1991, 195: 509-515. 10.1016/0014-4827(91)90403-H.View ArticlePubMedGoogle Scholar
- Resnick JL, Bixler LS, Cheng L, Donovan PJ: Longterm proliferation of mouse primordial germ cells in culture. Nature. 1992, 359: 550-551. 10.1038/359550a0.View ArticlePubMedGoogle Scholar
- Doetschmann TC, Eistetter H, Katz M, Schmidt W, Kemler R: The in vitro development of blastocyst-derived embryonic stem cell lines: formation of visceral yolk sac, blood islands and myocardium. J Embryol Exp Morphol. 1985, 87: 27-45.Google Scholar
- Brüstle O, Jones KN, Learish RD, Karram K, Choudhary K, Wiestler OD, Duncan ID, McKay RD: Embryonic stem cell-derived glial precursors: a source of myelinating transplants. Science. 1996, 285: 754-756.Google Scholar
- Johkura K, Cui L, Suzuki A, Teng R, Kamiyoshi A, Okamura S, Kubota S, Zhao X, Asanuma K, Okouchi Y, Ogiwara N, Tagawa Y, Sasaki K: Survival and function of mouse embryonic stem cell-derived cardiomyocytes in ectopic transplants. Cardiovasc Res. 2003, 58: 435-443. 10.1016/S0008-6363(02)00730-7.View ArticlePubMedGoogle Scholar
- Wobus AM, Wallukat G, Hescheler J: Pluripotent mouse embryonic stem cells are able to differentiate into cardiomyocytes expressing chronotropic responses to adrenergic and cholinergic agents and CAE channel blockers. Differentiation. 1991, 48: 173-182.View ArticlePubMedGoogle Scholar
- Okabe S, Forsberg-Nilsson K, Spiro AC, Segal M, McKay RD: Development of neuronal precursor cells and functional postmitotic neurons from embryonic stem cells in vitro. Mech Dev. 1996, 59: 89-102. 10.1016/0925-4773(96)00572-2.View ArticlePubMedGoogle Scholar
- Soria B, Skoudy A, Martin F: From stem cells to beta cells: new strategies in cell therapy of diabetes mellitus. Diabetologia. 2001, 44: 407-415. 10.1007/s001250051636.View ArticlePubMedGoogle Scholar
- Dani C, Smith AG, Dessolin S, Leroy P, Staccini L, V8illageois P, Darimont C, Ailhaud G: Differentiation of embryonic stem cells into adipocytes in vitro. J Cell Sci. 1997, 110: 1279-1285.PubMedGoogle Scholar
- zur Nieden NI, Kempka G, Ahr HJ: In vitro differentiation of embryonic stem cells into mineralized osteoblasts. Differentiation. 2003, 71: 18-27. 10.1046/j.1432-0436.2003.700602.x.View ArticlePubMedGoogle Scholar
- Phillips BW, Belmonte N, Vernochet C, Ailhaud G, Dani C: Compactin enhances osteogenesis in murine embryonic stem cells. Biochem Biophys Res Com. 2001, 284: 478-484. 10.1006/bbrc.2001.4987.View ArticlePubMedGoogle Scholar
- Buttery LDK, Bourne S, Xynos JD, Wood H, Hughes FJ, Hughes SPF, Episkopou V, Polak JM: Differentiation of osteoblasts and in vitro bone formation from murine embryonic stem cells. Tissue Engineering. 2001, 7: 89-99. 10.1089/107632700300003323.View ArticlePubMedGoogle Scholar
- Kramer J, Hegert C, Guan K, Wobus AM, Müller PK, Rohwedel J: Embryonic stem cell-derived chondrogenic differentiation in vitro: activation by BMP-2 and BMP-4. Mech Dev. 2000, 92: 193-205. 10.1016/S0925-4773(99)00339-1.View ArticlePubMedGoogle Scholar
- Hegert C, Kramer J, Hargus G, Muller J, Guan K, Wobus AM, Muller PK, Rohwedel J: Differentiation plasticity of chondrocytes derived from mouse embryonic stem cells. J Cell Sci. 2002, 115: 4617-4628. 10.1242/jcs.00171.View ArticlePubMedGoogle Scholar
- Yamada T, Placzek M, Tanaka H, Dodd J, Jessell TM: Control of cell pattern in the developing nervous system: polarizing activity of the floor plate and notochord. Cell. 1991, 64: 635-647. 10.1016/0092-8674(91)90247-V.View ArticlePubMedGoogle Scholar
- Johansson BM, Wiles MV: Evidence for involvement of activin A and bone morphogenetic protein 4 in mammalian mesoderm and hematopoetic development. Mol Cell Biol. 1995, 15: 141-151.PubMed CentralView ArticlePubMedGoogle Scholar
- Rosen V, Nove J, Song JJ, Thies RS, Cox K, Wozney JM: Responsiveness of clonal limb bud cell lines to bone morphogenetic protein 2 reveals a sequential relationship between cartilage and bone cell phenotypes. J Bone Miner Res. 1994, 9: 1759-1768.View ArticlePubMedGoogle Scholar
- Tanaka H, Murphy CL, Murphy C, Kimura M, Kawai S, Polak JM: Chondrogenic differentiation of murine embryonic stem cells: Effects of culture conditions and dexamethasone. J Cell Biochem. 2004, 93 (3): 454-462. 10.1002/jcb.20171.View ArticlePubMedGoogle Scholar
- zur Nieden NI, Kempka G, Ahr HJ: Molecular multiple endpoint embryonic stem cell test-a possible approach to test for the teratogenic potential of compounds. Toxicol Appl Pharmacol. 2004, 194: 257-269. 10.1016/j.taap.2003.09.019.View ArticlePubMedGoogle Scholar
- Denker AE, Haas AR, Nicoll SB, Tuan RS: Chondrogenic differentiation of murine C3H10T1/2 multipotential mesenchymal cells: I. Stimulation by bone morphogenetic protein-2 in high-density micromass cultures. Differentiation. 1999, 64: 67-76. 10.1046/j.1432-0436.1999.6420067.x.View ArticlePubMedGoogle Scholar
- Ikeda T, Kamekura S, Mabuchi A, Kou I, Seki S, Takato T, Nakamura K, Kawaguchi H, Ikegawa S, Chung UI: The combination of Sox5, sox6, and sox9 (the sox trio) provides signals sufficient for induction of permanent cartilage. Arthritis Rheum. 2004, 50: 3561-3573. 10.1002/art.20611.View ArticlePubMedGoogle Scholar
- Wei X, Messner K: Maturation-dependent durability of spontaneous cartilge repair in rabbit knee joint. J Biomed Mater Res. 1999, 46: 539-548. 10.1002/(SICI)1097-4636(19990915)46:4<539::AID-JBM12>3.0.CO;2-S.View ArticlePubMedGoogle Scholar
- Bos PK, DeGroot J, Budde M, Verhaar JAN, van O GJVM: Specific enzymatic treatment of bovine and human articular cartilage: implications for integrative cartilage repair. Arthritis Rheum. 2002, 46: 976-985. 10.1002/art.10208.View ArticlePubMedGoogle Scholar
- Hunziker EB: Articular cartilage repair: basic science and clinical progress. A review of current status and prospects. Osteoarthritis Cartilage. 2002, 10: 432-463. 10.1053/joca.2002.0801.View ArticlePubMedGoogle Scholar
- Oakes BW: Orthopaedic tissue engineering: from laboratory to the clinic. MJA. 2004, 180: S35-S38.PubMedGoogle Scholar
- Risbud MV, Sittinger M: Tissue engineering: advances in in vitro cartilage regeneration. Trends in Biotechnology. 2002, 20 (8): 351-356. 10.1016/S0167-7799(02)02016-4.View ArticlePubMedGoogle Scholar
- zur Nieden NI, Ruf LJ, Kempka G, Hildebrand H, Ahr HJ: Molecular markers in embryonic stem cells. Toxicol In vitro. 2001, 15: 455-461. 10.1016/S0887-2333(01)00071-6.View ArticlePubMedGoogle Scholar
- Farndale RW, Sayers CA, Barrett AJ: A direct spectrophotometric microassay for sulfated glycosaminoglycans in cartilage cultures. Connect Tissue Res. 1982, 9: 247-248.View ArticlePubMedGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.